VolitionRX Ltd (VNRX, Financial) is set to release its Q3 2024 earnings on Nov 15, 2024. The consensus estimate for Q3 2024 revenue is $0.65 million, and the earnings are expected to come in at -$0.07 per share. The full year 2024's revenue is expected to be $2.13 million and the earnings are expected to be -$0.32 per share. More detailed estimate data can be found on the Forecast page.
VolitionRX Ltd (VNRX, Financial) Estimates Trends
Over the past 90 days, revenue estimates for VolitionRX Ltd (VNRX) have declined from $3.05 million to $2.13 million for the full year 2024 and from $15.05 billion to $14.05 billion for 2025. Earnings estimates have increased from -$0.33 per share to -$0.32 per share for the full year 2024 and from -$0.19 per share to -$0.17 per share for 2025.
VolitionRX Ltd (VNRX, Financial) Reported History
In the previous quarter of June 30, 2024, VolitionRX Ltd's (VNRX) actual revenue was $0.40 million, which missed analysts' revenue expectations of $0.48 million by -16.81%. VolitionRX Ltd's (VNRX) actual earnings were -$0.08 per share, which beat analysts' earnings expectations of -$0.10 per share by 15.79%. After releasing the results, VolitionRX Ltd (VNRX) was up by 3.19% in one day.
VolitionRX Ltd (VNRX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 4 analysts, the average target price for VolitionRX Ltd (VNRX) is $3.28 with a high estimate of $5 and a low estimate of $2. The average target implies an upside of 328.66% from the current price of $0.76.
Based on GuruFocus estimates, the estimated GF Value for VolitionRX Ltd (VNRX, Financial) in one year is $4.58, suggesting an upside of 499.48% from the current price of $0.76.
Based on the consensus recommendation from 4 brokerage firms, VolitionRX Ltd's (VNRX, Financial) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
